Flatiron Health Announces Research to be Presented at American Society of Clinical Oncology 2020 Annual Meeting

NEW YORK, NY, May 14, 2020

Flatiron Health today announced eight abstracts were accepted for presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, to be held May 29–31.

The research being presented displays the broad impact that real-world data derived from electronic health records has across the oncology therapeutic lifecycle from discovery through development and ultimately in support of patient care,” said Dr. Michael Vasconcelles, chief medical officer at Flatiron. “It is a rich illustration of the knowledge that can be created when experts collaborate across the oncology ecosystem.”

The key areas studied include: 

  • Biomarkers that predict who may benefit from targeted treatments 
  • Treatment patterns at the end of life 
  • Barriers and solutions to clinical trial participation 
  • Novel clinico-genomic research

Flatiron collaborated on the accepted research with: University of Pennsylvania, Yale Cancer CenterCancer & Hematology Centers of Western MichiganFlorida Cancer Specialists, Hematology Oncology Associates of Central New York, Southeast Nebraska Cancer Center, Tennessee Oncology, West Cancer Center, Foundation Medicine, and Genentech, a member of the Roche Group.

Full abstracts will be posted at rwe.flatiron.com post-ASCO embargo on May 29. 


Poster Presentations

PD-L1 tumor proportion score and clinical benefit from first-line pembrolizumab in patients with advanced nonsquamous versus squamous non-small cell lung cancer

First Author: Deborah B. Doroshow, Icahn School of Medicine at Mount Sinai

Abstract: 9539

Poster: 305


Association of BRCA alteration (alt) type with real-world (RW) outcomes to PARP inhibitors (PARPi) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)

First Author: Emmanuel S. Antonarakis, Sidney Kimmel Comprehensive Cancer Center

Abstract: 5527

Poster: 108


Use of real-world data to understand barriers to interventional clinical trial enrollment in community oncology clinics (COC)

First Author: Johnetta Blakely, Tennessee Oncology 

Abstract: 2061

Poster: 53


The adoption of immune checkpoint inhibitors and patterns of care at the end of life

First Author: Fauzia Riaz, Yale School of Medicine

Abstract: 12027

Poster: 315


A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer

First Author: Michael W. Lu, Genentech

Abstract: TPS2087

Poster: 79


An automated EHR-based tool for identification of patients (pts) with metastatic disease to facilitate clinical trial pt ascertainment

First Author: Jeffrey J. Kirshner, Hematology Oncology Associates of Central New York

Abstract: 2051

Poster: 43


Characteristics and outcomes of real-world patients with microsatellite instability-high (MSI-H) solid tumors treated with pembrolizumab monotherapy after FDA approval

First Author: Tamara Snow, Flatiron Health

Abstract: 3060

Poster: 124


Real-world (RW) outcomes for advanced non-small cell lung cancer (aNSCLC) patients (pts) with EGFR exon 19 deletions (x19del) stratified by deletion size

First Author: Sai-Hong I. Ou, University of California Irvine Chao Comprehensive Cancer Center

Abstract: 9591

Poster: 357

About Flatiron

Flatiron Health is a healthcare technology and services company focused on accelerating cancer research and improving patient care. Our platform enables cancer researchers and care providers to learn from the experience of every patient. Currently, Flatiron partners with over 280 community cancer practices, seven major academic research centers and over 15 of the top therapeutic oncology companies. For more information, please visit flatiron.com or follow us @FlatironHealth.